DOCSLIB.ORG

COVID19 As Immunology Boot Camp: Anti-Viral Defense, Cytokine Biology & Prospects for Therapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
COVID19 As Immunology Boot Camp: Anti-Viral Defense, Cytokine Biology & Prospects for Therapy 9/19/2020 COVID19 as Immunology Boot Camp: Anti-Viral Defense, Cytokine Biology & Prospects for therapy Leonard H Calabrese Professor of Medicine Cleveland Clinic Lerner College of Medicine RJ Fasenmyer Chair of Clinical Immunology Department of Rheumatic and Immunologic Disease Cleveland Clinic @LCalabreseDO [email protected] COVID19 and Immunology 1 9/19/2020 Outline • Idealized clinical course of COVI19 • Immunology at 30,000 feet • Immunology of COVID-19 • Rheumatic therapies targeting cytokine storm • Unanswered questions 45000 40000 35000 30000 25000 Pubmed medRxiv 20000 bioRxiv Published articles Number Number of articles Peer reviewed 15000 No peer reviewed 10000 Curated 5000 AUGUST 10 2020 0 Feb-20 Mar-20 Apr-20 May-20 Jun-20 Jul-20 Aug-20 Sources: https://pubmed.ncbi.nlm.nih.gov, https://www.medrxiv.org, https://www.biorxiv.org 2 9/19/2020 ADAPTIVE ADVANCED CYTOKINE TYPE 1,2 3 IFN IMMUNITY FLOW DYSREGULATION INNATE IMMUNITY BIG PAMPS DATA DAMPS CD14+16+ Monocytes T Cell CYTOKINE STORM EXHAUSTION 3 9/19/2020 COVID-19 • Caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) • Single-stranded enveloped RNA virus • 7 human coronaviruses: - Severe disease: SARS-CoV, MERS-CoV, SARS-CoV-2 - Mild symptoms: HKU1, NL63, OC43 and 229E • Like SARS and MERS, SARS-CoV-2 believed to have moved from bats to an intermediate host – possibly Malayan Pangolin humans. Andersen KG, et al. Nat Med March 2020 Course of COVID-19 Infection – A Paradigm for Therapy ACT 1 ACT 2 ACT 3 asymptomatic non-severe symptomatic severe respiratory-inflammatory IMMUNE REPSONSE INNATE IMMUNE ADAPTIVE IMMUNE CYTOKINE OVER TIME ACTIVATION ACTIVATION MEDIATED RISK FOR STAGE 3 Self limiting in 80% SYNDROME Severe in 15-20% Viral engagement of Generation of specific Abs IL-6, IL-1, TNF, GM- Fatal 1-2% PAMPs and T cell response CSF, IFN, IFN AGE Low Type 1 IFN Release of DAMPS Immuno-Coagulopathy DM Quantitative viral load ASHD Renal disease HTN Viral response phase Hyperinflammatory phase Male sex Cytokine Storm Other Severity of Illness Severity IgM response day 5-10 IgG response day 7-14 Time Course ASHD = arteriosclerotic heart disease; HTN = hypertension; PAMP = pathogen-associated molecular pattern; DAMP = damage-associated molecular patterns; TNF = tumor necrosis factor; IL = Interleukin; GM-CSF = Granulocyte- macrophage colony-stimulating factor; IFN = interferon 4 9/19/2020 CCF Art Department Balance Calabrese LH, Marriot X Ann Rheum Dis Jan 2020 5 9/19/2020 Calabrese LH, Marriot X Ann Rheum Dis Jan 2020 CCOVID19 Calabrese LH, Marriot X Ann Rheum Dis Jan 2020 6 9/19/2020 Antiviral Immunity – 30,000 feet INNATE • Initiated at the cellular level following infections and replication • Viruses produce pathogenic RNA or DNA that are sensed by PRR (TLR RIG STING) • PRR engagement culminates in oligimerization of PRRs and activation of downstream transcription factors including interferon regulator factors(IRFs) and NFkB These launch 1. Cellular antiviral defenses IFN I & III and up regulation of IFN stimulated genes 2. Stimulation and coordination of innate and adaptive immune response via chemokines and cytokines McNab F et al Nat Reviews Immunology 15:87,2015 Evolution of the immune system and Viral Invasion Karim M. Yatim, and Fadi G. Lakkis CJASN 2015;10:1274- 1281 ©2015 by American Society of Nephrology 7 9/19/2020 PNAS first published July 9, 2020 https://doi.org/10.1073/pnas.2008410117 Flow of T-cell Memory Acute MILD viral infection COVID19 INFECTION Naïve T cell Functional memory CTL Central and peripheral 4 to 6 hours • 95% die • SELF-renewal IL-7, IL-15 x 10 days 106 week RECOVERY CTL effector cell 2 to 3 days inflammation 10-14 days 8 9/19/2020 Act 3 – Hyper-inflammation PAMP Driven DAMP DRIVEN Virus- Necroptosis Tissue tropism Local-regional Target organs damage Viremia Cells of innate immunity Bacteria Secondary HLH/MAS – lessons learned Cytokine Storm / Cytokine Release Syndrome loosely applies to wide variety of conditions also referred to as (SIRS) that can be triggered by a variety of factors such as infections and certain drugs Acute Primary Immunodeficiency States HLH inflammation Malignancy associated Castelmans End-organ Lymphoma / Rx CAR-T cell therapy damage Auto inflammatory diseases – JIA AOS Death Infections Influenza, EBV, COVID19 9 9/19/2020 Capable of predicting clinical outcomes more than 10 days in advance with 90% accuracy LDH >365 U/L = tissue damage CRP > 4.1mg% = inflammation Lymphocytes < 14.7% = immune activation VIRAL ESCAPE---------------PAMPS Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 PAMP DRIVEN Cell and animal models of SARS-CoV2 IFA and other viruses for in depth transcriptional responses Highlights • SARS-CoV-2 infection induces low IFN-I and -III levels with a moderate ISG response • Strong chemokine expression is consistent across in vitro, ex vivo, and in vivo models • Low innate antiviral defenses and high pro- inflammatory cues contribute to COVID-19 Blanco-Melo et al., 2020, Cell 181, 1–10 May 28, 2020 ª 2020 Elsevier Inc. https://doi.org/10.1016/j.cell.2020.04.026 10 9/19/2020 COVID19 and BIG DATA • Integrating large numbers of immune parameters( 200+) and clinical features • Multi-parameter flow • Transcriptomics • Proteomics • Phosphoproeomics • Single cell analysis • Immunologic Age Nature AUG 20 2020 11 9/19/2020 N=90 COVID19 n=71 controls T cell activation and non T B cell expansion ( myeloid compartment) Integrated analysis of ~200 immune and >30 clinical features revealed activation of T cell and B cell subsets, but only in some patients. COVID19 immune responses are heterogeneous and some correlate with disease severity Science 15 Jul 2020:eabc8511DOI: 10.1126/science.abc8511 www.clinincaltrials.gov • August 28 +/- 3000 IFN Rx JAKi 1 GM-CSF Rx Anti-GM-CSF IL-7 ? Anti- pDC 12 9/19/2020 Immunotherapeutic Strategies for COVID-19 Cytokine Release and Beyond Kinase Inhibitors tofacitinib, baricitinib, Targeted ruxolitinib Therapy others Non specific Glucocorticoids, IL-1, IL-6, calcineurin- TNF, nhibitors, GMCSF M-tor-inhibitors Gamma IFN IMMUNOTHERAPY Tolerogenic therapies Passive Therapy IVIG, T regs immune plasma Low dose IL-2 Specific Abs CELLULAR THERAPIES NK cell therapies Anti-pDC others 30,000 foot view of COVID19 trial design 1. Diagnosis 2. Triage by severity 3. Comparator 1. Historical (non RCT) 2. SOC CHANGING!!! 3. Other 13 9/19/2020 Candidates • IL6 inhibitors • IL-1 inhibitors • Glucocorticoids • Kinase inhibitors –JAKi, PI3K,BTKi,TKIs others • GM-CSF inhibitors Cytokine Release Syndrome Course after tocilizumab Critical Care Med 2017 14 9/19/2020 IL-6 inhibitors • Advantage: approved agents for numerous autoimmune and auto-inflammatory syndromes including CAR-T cell cytokine storm • Administration: IV dosing, frequency undetermined, narrow therapeutic index (1-2x) • Disadvantage/caution: associated with SIEs in chronic use, increased liver enzymes, decreased platelets, WBC Anti-IL6 and COVID-19 Phase 1 Phase 2 Phase 3 Phase 4 Clazakinumab NCT04348500 NCT04359901 Sarilumab NCT04386239 NCT04315298 NCT04322773 NCT04333914 NCT04335071 NCT04315480 Tocilizumab NCT04445272 NCT04330638 NCT04377750 NCT04370834 NCT04331808 NCT04322773 15 9/19/2020 In these intubated patients, improvisent of survival: HR=0.55 (95% CI 0.33, 0.90) (red) and in spite an increasesarilumab of bacterial infections: (54% vs 26%) (orange) IL-1 Product of inflammasome activation DAMPS 16 9/19/2020 IL-1 • Advantages: Approved in various autoimmune/auto-inflammatory disorders (Cryopyrinopathies,JIA, AOS, RA) off label in many including sHLH/MAS and sepsis • Administration: Three agents in trial anakinra, canakinumab and rilonacept • Disadvantages/caution: Anakinra wide therapeutic index (100mgQD-3500mgQD) CALABRESE L, CALABRESE C. CYTOKINE RELEASE SYNDROME AND THE PROSPECTS FOR IMMUNOTHERAPY WITH COVID-19 PART 2: THE ROLE OF IL-1 CCJM JULY 2020 Anakinra – 3: 52 patients • No patient on mechanical ventilation • Anakinra: 200 mg SC /day 3 days and 100 mg SC /day 7 days • Historical controls Thelancet.com/rheumatology Published online May 29, 2020 17 9/19/2020 Glucocorticoids • GC known to modulate the immune system since 1924 with landmark by Dale et al. work in the 70s documenting immunosuppressive effects • More recently Human Immunome studies demonstrated suppression of NF-kB, apoptosis and cell death differentially effecting T and B cells and NK cells in humans (Olnes M et al Sci Reports 6:23002,16) • Previous work in SARS MERS& severe influenza mixed/underpowered and suffer from heterogeneity of agent/dose/duration • Currently over 40 trials using GC in COVID19 on clininctrial.gov Dexamethasone COVI9-19 : Dexamethasone reduced deaths by one-third in patients receiving invasive mechanical ventilation (29.0% vs. 40.7%, RR 0.65 [95% CI 0.51 to 0.82]; p NNT=8 for mortality 18 9/19/2020 Course of COVID-19 Infection – A Paradigm for Therapy ACT 1 ACT2 ACT 3 asymptomatic non-severe symptomatic severe respiratory-inflammatory IMMUNE REPSONSE INNATE IMMUNE ADAPTIVE IMMUNE CYTOKINE RELEASE OVER TIME ACTIVATIONAntivirals ACTIVATION SYNDROME RISK FOR STAGE 3 Self limiting in 80% Viral engagement of Generation of specific Abs IL-6, IL-1, TNF, GM- Severe in 15-20% PAMPsType 1 and 3 IFNsand T cell response CSF, IFN, IFN Fatal 1-2% Low TypeImmune 1 IFN plasmaRelease of DAMPS Coagulopathy AGE Complement DM Quantitative viral load ASHD Renal disease HTN Viral response phase Hyperinflammatory phase Male sex Cytokine Storm IgM response day 5-10 Other Severity of Illness Severity Immunomodulatory therapies targeting IgG response day 7-14 IL-1,TNF, IL-6,GMCSF Glucocorticoids, kinase inh Xrt-PD4 i Time Course others ASHD = arteriosclerotic heart disease; HTN = hypertension; PAMP = pathogen-associated molecular pattern; DAMP = damage-associated molecular patterns; TNF = tumor necrosis factor; IL = Interleukin; GM-CSF = Granulocyte- macrophage colony-stimulating factor; IFN = interferon • Timing is critical but its not about chronologic timing • Early in identifying Endotypes / Immunotypes • Lack of Biomarkers correlating correlating with Endotypes or Immunotypes of importance 2020 Jul; 19(7): 102567.
Load more

Recommended publications
  • The Use of Biologic Agents in the Treatment of Oral Lesions Due to Pemphigus and Behçet's Disease: a Systematic Review
    Davis GE, Sarandev G, Vaughan AT, Al-Eryani K, Enciso R. The Use of Biologic Agents in the Treatment of Oral Lesions due to Pemphigus and Behçet’s Disease: A Systematic Review. J Anesthesiol & Pain Therapy. 2020;1(1):14-23 Systematic Review Open Access The Use of Biologic Agents in the Treatment of Oral Lesions due to Pemphigus and Behçet’s Disease: A Systematic Review Gerald E. Davis II1,2, George Sarandev1, Alexander T. Vaughan1, Kamal Al-Eryani3, Reyes Enciso4* 1Advanced graduate, Master of Science Program in Orofacial Pain and Oral Medicine, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA 2Assistant Dean of Academic Affairs, Assistant Professor, Restorative Dentistry, Meharry Medical College, School of Dentistry, Nashville, Tennessee, USA 3Assistant Professor of Clinical Dentistry, Division of Periodontology, Dental Hygiene & Diagnostic Sciences, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA 4Associate Professor (Instructional), Division of Dental Public Health and Pediatric Dentistry, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA Article Info Abstract Article Notes Background: Current treatments for pemphigus and Behçet’s disease, such Received: : March 11, 2019 as corticosteroids, have long-term serious adverse effects. Accepted: : April 29, 2020 Objective: The objective of this systematic review was to evaluate the *Correspondence: efficacy of biologic agents (biopharmaceuticals manufactured via a biological *Dr. Reyes Enciso, Associate Professor (Instructional), Division source) on the treatment of intraoral lesions associated with pemphigus and of Dental Public Health and Pediatric Dentistry, Herman Ostrow Behçet’s disease compared to glucocorticoids or placebo. School of Dentistry of USC, Los Angeles, California, USA; Email: [email protected].
    [Show full text]
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • The Management of Sepsis: What's New in 2013
    The Management of Sepsis: What’s New in 2013 Mitchell M. Levy MD, FCCM Professor of Medicine Chief, Division of Pulmonary, Sleep, and Critical Care Warren Alpert Medical School of Brown University Providence, RI Disclosures • Personal: – Financial: • None • SSC – Financial: • None • No industry support since 2006 Projected Incidence of Severe Sepsis in the US: 2001‐2050 1,800 600 Severe Sepsis Cases ) 3 US Population 1,600 500 1,400 1,200 400 Sepsis Cases (x10 1,000 800 300 Total US Population (million) US Total 2001 2025 2050 Angus DC, et al. JAMA 2000;284:2762-70. Year Angus DC, et al. Crit Care Med 2001. In Press. Pathophysiology Sepsis as Cytokine Storm • Sepsis presentation – Fever, shock, respiratory failure • Pro‐inflammatory cytokines TNFα, IL‐1, IL‐6 – All increased in sepsis • Encouraging results in animal models pre‐ treated with therapeutics that blocked pro‐ inflammatory cytokines Traditional view of sepsis and its pathophysiology Virulent pathogens (pneumococci, meningococcus, • VirulentGroup A strep, pathogens: S. aureus, Clostrida spp.) pneumococcus,Pro-inflammatory markers-cytokines, S. aureus, Groupchemokines A strep,C’ Clostridia, meningococci C, ROS RNS kinins, procoagulants • Proinflammatory mediators- Early onset septic shock, MODS cytokines, chemokines, procoagulants, kinins, ROI, RNI, C’ • Young, previously healthy patients with rapid onset septic shock - fits our animal models (Hotchkiss and Karl N Engl J Med 2003;348:138) /8 TLR’s are the major pattern recognition receptors of innate immunity PAMPs DAMPs HSP Heparan Hyaluronate Fibrinogen Microorganisms Biglycan Surfactant A HMGB-1 Heme MRP8/14 Histone 5 PRRs Immune cells NLRs TLRs CLRs CDRs RLHs ASC Caspase-1 & 5 NF-κB ASC NALP1 & 3 Pyrin Host-derived mediators Cinel and Opal CCM 2009:291 Genomic Storm Xiao et al.
    [Show full text]
  • Targeted Review List Kaiser HMO, Multi-Choice, PPO, Senior Advantage Effective 1/01/2020
    Kaiser Permanente Georgia Region Provider Targeted Review List Kaiser HMO, Multi-Choice, PPO, Senior Advantage Effective 1/01/2020 The Affiliated Community Physician is responsible for verification of member eligibility and benefit coverage by logging on to KP Online-Affiliate or calling Member Services at 404-261- 2590. Failure to obtain authorization prior to providing the services listed below will result in a denial of payment. A medical necessity review decision will be issued to your office and to the member upon completion of the review process. Receipt of complete clinical information with the initial request will expedite the process. Authorization for approval of services based on medical necessity is never a guarantee of payment which must also meet the criteria of member eligibility and benefit availability. The Kaiser Permanente Quality Resource Management Department requires authorization of all post stabilization care including observation and inpatient admissions. Please call our Emergency Care Management hub at 404-365-4254 for authorization. For emergency authorization of home health or durable medical services after regular business hours, contact 404-365-0966 or 800-611-1811 to speak with the QRM case manager on call. Hours of Operation: Quality Resource Management Department Monday through Friday 8:00 am – 5:00 pm 404-364-7320/800-221-2412 Member Services Department Monday through Friday 7:00 am – 7:00 pm 404-261-2590 Emergency Care Management Hub Available 24/7 404-365-4254 Medical necessity review is required for the following services/conditions: HMO members require QRM review and approval for reimbursement of any non- contracted, out of network (office based, outpatient, inpatient) services.
    [Show full text]
  • Review Anti-Cytokine Biologic Treatment Beyond Anti-TNF in Behçet's Disease
    Review Anti-cytokine biologic treatment beyond anti-TNF in Behçet’s disease A. Arida, P.P. Sfikakis First Department of Propedeutic Internal ABSTRACT and thrombotic complications (1-3). Medicine Laikon Hospital, Athens, Unmet therapeutic needs in Behçet’s Treatment varies according to type and University Medical School, Greece. disease have drawn recent attention to severity of disease manifestations. Cor- Aikaterini Arida, MD biological agents targeting cytokines ticosteroids, interferon-alpha and con- Petros P. Sfikakis, MD other than TNF. The anti-IL-17 anti- ventional immunosuppressive drugs, Please address correspondence to: body secukinumab and the anti-IL-2 such as azathioprine, cyclosporine-A, Petros P. Sfikakis, MD, receptor antibody daclizumab were not cyclophosphamide and methotrexate, First Department of Propedeutic superior to placebo for ocular Behçet’s and Internal Medicine, are used either alone or in combination Laikon Hospital, in randomised controlled trials, com- for vital organ involvement. During the Athens University Medical School, prising 118 and 17 patients, respec- last decade there has been increased use Ag Thoma, 17, tively. The anti-IL-1 agents anakinra of anti-TNF monoclonal antibodies in GR-11527 Athens, Greece. and canakinumab and the anti-IL-6 patients with BD who were refractory E-mail: [email protected] agent tocilizumab were given to iso- to conventional treatment or developed Received on June 7, 2014; accepted in lated refractory disease patients, who life-threatening complications (4, 5). revised form on September 17, 2014. were either anti-TNF naïve (n=9) or Anti-TNF treatment has been shown to Clin Exp Rheumatol 2014; 32 (Suppl. 84): experienced (n=18).
    [Show full text]
  • Presenters: Philip R
    UC Davis Dermatology Online Journal Title Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma Permalink https://escholarship.org/uc/item/8109j4cw Journal Dermatology Online Journal, 20(1) Authors Cohen, Philip R Kurzrock, Razelle Publication Date 2014 DOI 10.5070/D3201021241 License https://creativecommons.org/licenses/by-nc-nd/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Volume 20 Number 1 January 2014 Case Report Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma Philip R. Cohen, MD1 and Razelle Kurzrock, MD2 Dermatology Online Journal 20 (1): 1 1Division of Dermatology, University of California San Diego, San Diego, California; 2Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California San Diego—Moores Cancer Center, La Jolla, California. Correspondence: Philip R. Cohen, MD 10991 Twinleaf Court San Diego, CA 92131-3643 [email protected] Abstract Background: Anakinra is a recombinant form of interleukin-1 receptor antagonist. It is the drug of choice for Schnitzler syndrome and cryopyrin-associated periodic syndromes. It has also recently been demonstrated to have activity in the treatment of the non-Langerhans cell histiocytosis known as Erdheim-Chester disease. Purpose: To describe the activity of anakinra in a patient with co-existing lichen planus and Erdheim-Chester disease. Methods: A 43-year-old woman with progressive Erdheim-Chester disease presented for management of her night sweats and chills, systemic skeletal bone pain, and neurologic (diabetes insipidus) manifestations. She also had widespread cutaneous lichen planus.
    [Show full text]
  • Challenges and Approaches for the Development of Safer Immunomodulatory Biologics
    REVIEWS Challenges and approaches for the development of safer immunomodulatory biologics Jean G. Sathish1*, Swaminathan Sethu1*, Marie-Christine Bielsky2, Lolke de Haan3, Neil S. French1, Karthik Govindappa1, James Green4, Christopher E. M. Griffiths5, Stephen Holgate6, David Jones2, Ian Kimber7, Jonathan Moggs8, Dean J. Naisbitt1, Munir Pirmohamed1, Gabriele Reichmann9, Jennifer Sims10, Meena Subramanyam11, Marque D. Todd12, Jan Willem Van Der Laan13, Richard J. Weaver14 and B. Kevin Park1 Abstract | Immunomodulatory biologics, which render their therapeutic effects by modulating or harnessing immune responses, have proven their therapeutic utility in several complex conditions including cancer and autoimmune diseases. However, unwanted adverse reactions — including serious infections, malignancy, cytokine release syndrome, anaphylaxis and hypersensitivity as well as immunogenicity — pose a challenge to the development of new (and safer) immunomodulatory biologics. In this article, we assess the safety issues associated with immunomodulatory biologics and discuss the current approaches for predicting and mitigating adverse reactions associated with their use. We also outline how these approaches can inform the development of safer immunomodulatory biologics. Immunomodulatory Biologics currently represent more than 30% of licensed The high specificity of the interactions of immu- biologics pharmaceutical products and have expanded the thera- nomodulatory biologics with their relevant immune Biotechnology-derived peutic options available
    [Show full text]
  • WHO EML Application Tocilizumab
    WHO EML Application Tocilizumab Condition Juvenile Idiopathic Arthritis 1 Summary statement of the proposal for inclusion. The application proposes the inclusion of Tocilizumab on the complementary list of the EML/EMLc/both for the treatment of Systemic Onset Juvenile Idiopathic Arthritis (SOJIA). The rationale for the complementary list is that the use of this drug requires specialised care. The proposed listing on both the EML and EMLc reflects the fact that JIA affects children through adolescence and into adulthood. This rationale is consistent with the listing for the anti-TNF biologics currently listed for JIA. Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease of childhood, affecting approximately one per 1000 children (1, 2). JIA is characterised by joint inflammation of more than 6 weeks’ duration, with onset before age sixteen years and where no other cause is found (2). JIA is an autoimmune, non-infective, inflammatory joint disease, the cause of which remains poorly understood with both genetic and environmental contributions (3). It is a distinct entity from rheumatoid arthritis, differing in clinical presentations, prognosis, disease outcomes and treatment approaches. The age of onset in JIA is typically young, with a peak incidence between 1-3 years of age, although the disease persists into adulthood in approximately 50% of cases (4). Even in patients in whom the inflammatory disease resolves, joint or extra-articular damage – with associated disability – are common and if not treated then can result in irreversible sequelae and impact on quality of life (5). Current treatment approaches for children with JIA aim for normal physical and psychosocial functioning, and with access to modern treatments, good outcomes are a realistic and achievable goal for many children with this condition (6) .
    [Show full text]
  • Specialty Guideline Management
    Reference number 1800-A SPECIALTY GUIDELINE MANAGEMENT ARCALYST (rilonacept) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. FDA-Approved Indications Treatment of Cryopyrin Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 years of age and older. All other indications are considered experimental/investigational and not medically necessary. II. CRITERIA FOR INITIAL APPROVAL Cryopyrin-associated periodic syndrome (CAPS) Authorization of 12 months may be granted for treatment of CAPS when all of the following criteria are met: A. Member has a diagnosis of familial cold auto-inflammatory syndrome (FCAS) with classic signs and symptoms (i.e., recurrent, intermittent fever and rash that were often exacerbated by exposure to generalized cool ambient temperature) or Muckle-Wells syndrome (MWS) with classic signs and symptoms (i.e., chronic fever and rash of waxing and waning intensity, sometimes exacerbated by exposure to generalized cool ambient temperature). B. Member has functional impairment limiting the activities of daily living. III. CONTINUATION OF THERAPY Authorization of 12 months may be granted for all members (including new members) who are using the requested medication for an indication outlined in Section II and who achieve or maintain positive
    [Show full text]
  • Prior Authorization Policy
    PRIOR AUTHORIZATION POLICY POLICY: Inflammatory Conditions – Arcalyst® (rilonacept for subcutaneous injection Regeneron Pharmaceuticals) DATE REVIEWED: 11/06/2019; selected revision 04/01/2020 OVERVIEW Arcalyst is an interleukin-1 (IL-1) blocker indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children aged 12 years and older.1 Arcalyst, also known is a recombinant dimeric fusion protein that blocks IL-1β signaling and to a lesser extent also binds IL-1α and IL-1 receptor antagonist (IL-1ra). In adults ≥ 18 years of age, Arcalyst is initiated with a loading dose of 320 mg delivered as two subcutaneous (SC) injections of 160 mg on the same day at two separate sites. Dosing is continued with 160 mg once weekly as a single injection. In adolescents aged 12 to 17 years, therapy is initiated with a loading dose of 4.4 mg/kg, up to a maximum of 320 mg, delivered as one or two SC injections with a maximum single-injection volume of 2 mL. If the initial dose is two injections, then patients should be given Arcalyst on the same day at two separate sites. In adolescents, dosing is continued with 2.2 mg/kg, up to a maximum of 160 mg, once weekly as a single injection. Disease Overview CAPS is a rare inherited inflammatory disease associated with overproduction of IL-1. CAPS encompasses three rare genetic syndromes. FCAS, MWS, and neonatal onset multisystem inflammatory disorder (NOMID) or chronic infantile neurological cutaneous and articular syndrome (CINCA) are thought to be one condition along a spectrum of disease severity.2-3 FCAS is the mildest phenotype and NOMID is the most severe.
    [Show full text]
  • Asthma Agents
    APPROVED PA Criteria Initial Approval Date: July 10, 2019 Revised Date: January 20, 2021 CRITERIA FOR PRIOR AUTHORIZATION Asthma Agents BILLING CODE TYPE For drug coverage and provider type information, see the KMAP Reference Codes webpage. MANUAL GUIDELINES Prior authorization will be required for all current and future dose forms available. All medication-specific criteria, including drug-specific indication, age, and dose for each agent is defined in Table 1 below. Benralizumab (Fasenra®) Dupilumab (Dupixent®) Mepolizumab (Nucala®) Omalizumab (Xolair®) Reslizumab (Cinqair®) GENERAL CRITERIA FOR INITIAL PRIOR AUTHORIZATION: (must meet all of the following) • Must be approved for the indication, age, and not exceed dosing limits listed in Table 1. • Must be prescribed by or in consultation with a pulmonologist, allergist, or immunologist.1,2 • For all agents listed, the preferred PDL drug, which treats the PA indication, is required unless the patient meets the non-preferred PDL PA criteria. • Must have experienced ≥ 2 exacerbations within the last 12 months despite meeting all of the following (exacerbation is defined as requiring the use of oral/systemic corticosteroids, urgent care/hospital admission, or intubation: o Patient adherence to two long-term controller medications, including a high-dose inhaled corticosteroid 1,2 (ICS) and a long-acting beta2-agonist (LABA) listed in Table 2. ▪ Combination ICS/LABA and ICS/LABA/LAMA products meet the requirement of two controller medications. o Patient must have had an adequate trial (at least 90 consecutive days) of a leukotriene modifier or a long-acting muscarinic antagonist (LAMA) as a third long-term controller medication listed in Table 2.
    [Show full text]
  • Cimzia (Certolizumab Pegol) AHM
    Cimzia (Certolizumab Pegol) AHM Clinical Indications • Cimzia (Certolizumab Pegol) is considered medically necessary for adult members 18 years of age or older with moderately-to-severely active disease when ALL of the following conditions are met o Moderately-to-severely active Crohn's disease as manifested by 1 or more of the following . Diarrhea . Abdominal pain . Bleeding . Weight loss . Perianal disease . Internal fistulae . Intestinal obstruction . Megacolon . Extra-intestinal manifestations: arthritis or spondylitis o Crohn's disease has remained active despite treatment with 1 or more of the following . Corticosteroids . 6-mercaptopurine/azathioprine • Certollizumab pegol (see note) is considered medically necessary for persons with active psoriatic arthritis who meet criteria in Psoriasis and Psoriatic Arthritis: Biological Therapies. • Cimzia, (Certolizumab Pegol), alone or in combination with methotrexate (MTX), is considered medically necessary for the treatment of adult members 18 years of age or older with moderately-to-severely active rheumatoid arthritis (RA). • Cimzia (Certolizumab pegol is considered medically necessary for reducing signs and symptoms of members with active ankylosing spondylitis who have an inadequate response to 2 or more NSAIDs. • Cimzia (Certolizumab Pegol) is considered investigational for all other indications (e.g.,ocular inflammation/uveitis; not an all-inclusive list) because its effectiveness for indications other than the ones listed above has not been established. Notes • There are several brands of targeted immune modulators on the market. There is a lack of reliable evidence that any one brand of targeted immune modulator is superior to other brands for medically necessary indications. Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab), Simponi (golimumab), Simponi Aria (golimumab intravneous), and Stelara (ustekinumab) brands of targeted immune modulators ("least cost brands of targeted immune modulators") are less costly to the plan.
    [Show full text]